News

DENVER, Colo. – The publication of the Eighth Edition of the Tumor, Node and Metastasis (TNM) Classification of Lung Cancer will provide physicians around the world access to new data to more precisely stage and treat cases of lung cancer. That data, collected by the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee and presented at the 16th World Conference on Lung Cancer (WCLC) in Denver on Tuesday, Sept. 8, 2015 at the Colorado Convention Center, will be published in 2016.

DENVER, Colo. — “Despite tremendous advances in treating lung cancer, there is still no specific, diagnostic approach available to treat women,” said Dr. Silvia Novello, Associate Professor, Department of Oncology, University of Turin-Italy. Dr. Novello made her remarks while opening the press briefing today at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC), which covered many topics including a new edition of the TNM Staging System, the new WHO Classification on Tumors of the Lung and increases in the number of lung cancer in patients who never smoked.

The International Association for the Study of Lung Cancer (IASLC) will hold a press conference on Wednesday, Sept. 9, 2015 at 9:45 a.m. MDT to reveal findings from key abstracts detailing advances in lung cancer study and research. Full presentations of these abstracts and other lung cancer study advancements will take place throughout the 16th World Conference on Lung Cancer (WCLC).

DENVER, Colo. (Monday, September 7, 2015) — Groundbreaking research presented today by international leaders in lung cancer highlighted the benefits of focusing on the prevention of lung cancer, of spreading the message about the dangers of tobacco and of improving our regulatory process so unnecessary lives aren’t lost. Encouraging data about therapies to combat wasting and increase life expectancy were also shared at the at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC), which also released a new statement on Tobacco Control and Smoking Cessation.

The International Association for the Study of Lung Cancer (IASLC) will hold a press conference on Tuesday, Sept. 8, 2015 at 9:45 a.m. MDT to reveal findings from key abstracts detailing advances in lung cancer study and research. Full presentations of these abstracts and other lung cancer study advancements will take place throughout the 16th World Conference on Lung Cancer (WCLC).

DENVER, Colo. — Adding the angiogenesis inhibitor bevacizumab to standard treatment for malignant pleural mesothelioma (MPM) increases life expectancy without severe toxicity, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). The French multicenter randomized phase 3 trial data was presented by Dr. Arnaud Scherpereel, Head of the Pulmonary and Thoracic Oncology Department and Professor at the University Hospital (CHU) of Lille, France.

Pages